Trial Profile

Phase II study of AKP07 (Tacrolimus) for the treatment of atopic dermatitis.

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 14 May 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tacrolimus (Primary)
Indications Atopic dermatitis
Focus Therapeutic Use
Sponsors Lipidor

Most Recent Events

14 May 2020 New trial record
07 May 2020 According to a Lipidor media release,minor delays based on the Covid-19 outbreak the timetable for the start of this trial is being shifted. The company will return with an updated timetable for the project
07 May 2020 According to a Lipidor media release, the company announced its objective of initiating a Phase II study of AKP07 (Tacrolimus) for the treatment of atopic dermatitis in the first half of 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com